aestheticprimal
Independent commentary from @aestheticprimal on endocrine physiology and topical androgen effects. Produces concise, technically minded observations rather than firm investment recommendations.
Past bets that played out
Contributions center on physiological effects: notes that an unspecified substance reduces FSH and LH modestly in a dose-dependent way, and discussion that topical testosterone/DHT effects on the HPG axis are dose‑dependent. These posts do not reference specific companies, drugs, catalysts, or tradable assets.
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
What this channel is watching now
Current mentions track DHT and LH (each cited once) with moderate conviction. Commentary is research- and physiology-focused rather than market-focused.
Latest videos and market context
No video content detected — recent source posts are short-form X commentary and replies about hormonal effects and personal skincare experiences.
_aestheticprimal_ @aestheticprimal 57m interesting client observation doesn't remember the last time he slept through...
Anecdotal claim: a client reports improved nocturia/sleep continuity after taking 20mg vitamin K2 (MK-4) before bed for 4 days. No clinical data, no identifiable public-company catalyst, and unclear market relevance.
_aestheticprimal_ @aestheticprimal 29m GH follows the same pattern as LH, in the way it rises in effort of overcompen...
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
_aestheticprimal_ @aestheticprimal 18h low Progesterone is the reason she keeps on imagining fake scenarios and askin...
A social-media joke/comment about progesterone and relationship behavior; no financial, economic, or market-relevant information.
_aestheticprimal_ @aestheticprimal Jul 22 I've witnessed interesting reductions in LH whereas Testosterone shot up fr...
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Proof-backed call history
Activity consists of short, evidence-minded posts and replies about androgen physiology, topical testosterone, and anecdotal skincare observations. Two evaluated recommendations show an average return of 2.09% across two items with a 100% win rate, per available summary metadata.
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
Content discusses human endocrinology (GH/LH/IGF-1, insulin, Leydig cell sensitivity, HPG axis) and makes no explicit market, company, sector, macro, or investable-asset claims. Not directly translatable into a tradable catalyst without additional context (e.g., drug/company linkage, clinical results, regulation, product demand).
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
Anecdotal social post claims higher-dose Vitamin K2 (MK-4) plus Vitamin E (mixed tocopherols) improved testosterone/LH dynamics, with commentary that high LH can indicate reduced Leydig-cell sensitivity and oxidative stress/circadian factors. This is not investable as a catalyst by itself, but it loosely reinforces an existing supplement/ingredients demand narrative (fat-soluble vitamins, antioxidant positioning).
A social-media health claim suggests brushing teeth with magnesium increases calcium ion density in enamel and whitens teeth “from the inside out.” This is not a market-moving event and contains no company/product identifiers; at best it implies a niche consumer trend toward DIY/mineral-based oral care.
A social-media health claim suggests brushing teeth with magnesium increases calcium ion density in enamel and whitens teeth “from the inside out.” This is not a market-moving event and contains no company/product identifiers; at best it implies a niche consumer trend toward DIY/mineral-based oral care.
A social-media health claim suggests brushing teeth with magnesium increases calcium ion density in enamel and whitens teeth “from the inside out.” This is not a market-moving event and contains no company/product identifiers; at best it implies a niche consumer trend toward DIY/mineral-based oral care.
Commentary about an unspecified substance reducing FSH and LH modestly, in a dose-dependent manner. No company, drug, catalyst, or tradable asset is identified.
Discussion about physiological effects of topical testosterone and DHT on HPG axis activity; no explicit market, company, product, or investable asset referenced.
About this channel
@aestheticprimal posts concise physiological commentary on X (@aestheticprimal). Content emphasizes mechanistic observations (e.g., FSH/LH modulation, topical testosterone effects) and does not promote investable instruments or specific products.
@aestheticprimal
Most recognized assets
Unlock the full track record
Follow @aestheticprimal on X for brief, technically oriented commentary about endocrine physiology. Not investment advice—posts are informational and non‑transactional.